Medmira ( (TSE:MIR) ) has shared an update.
MedMira Inc. reported its Q2 FY2025 financial results, highlighting significant regulatory achievements, including Health Canada approval for its Multiplo® Rapid TP/HIV Test and Reveal® Rapid HIV Test. The company expanded its market reach through new distribution agreements in Canada and the USA. Despite recording a net loss and increased operating expenses due to clinical trials, MedMira anticipates revenue growth driven by the demand for its testing solutions. The company is also pursuing regulatory clearance for home testing applications, which could further enhance its market position.
More about Medmira
MedMira Inc. operates in the medical diagnostics industry, focusing on the development and distribution of rapid testing solutions. Its primary products include the Multiplo® Rapid TP/HIV Test and the Reveal® Rapid HIV Test, with a market focus on North America.
YTD Price Performance: -18.18%
Average Trading Volume: 71,308
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$68.25M
See more insights into MIR stock on TipRanks’ Stock Analysis page.